HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. 1995

C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
Division of Virology, University College London Medical School, London.

The response of HIV-1 to initial zidovudine (ZDV) treatment was assessed in 11 patients with severe HIV disease. We quantified serum HIV-1 concentrations and mutations associated with ZDV resistance by culture-independent methods. There was a prompt fall in serum HIV-1 RNA within 1-2 days of treatment with maximum suppression by seven days, which was paralleled by changes in serum p24 antigen (p24 Ag). Serum RNA started to return to pretreatment levels within weeks. The HIV reverse transcriptase (RT) gene in most patients developed mutations associated with drug resistance within months and as early as 25 days on therapy in one patient. The codon changes were not sufficient to explain the early return of serum HIV-1 RNA levels and their patterns continued to evolve after patients stopped taking ZDV. The significance of these findings is discussed in relation to the limited long-term efficacy of ZDV. The dynamic time course of viral load and RT responses to ZDV is of particular importance in short-term interventions such as pregnancy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
September 2002, Clinics in laboratory medicine,
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
March 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
June 1995, Journal of virology,
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
May 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
August 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
July 1999, Lancet (London, England),
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
July 1999, Lancet (London, England),
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
July 1999, Lancet (London, England),
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
December 1996, Antiviral therapy,
C Loveday, and S Kaye, and M Tenant-Flowers, and M Semple, and U Ayliffe, and I V Weller, and R S Tedder
March 2002, AIDS (London, England),
Copied contents to your clipboard!